Development of Corneal-Endothelial Regenerative Medicine Involving Cultivated Human Corneal Endothelial Cell Injection

Development of Corneal-Endothelial Regenerative Medicine Involving Cultivated Human Corneal Endothelial Cell Injection - CHCEC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTa050190118

Enrollment

Registered

2020-03-05

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous Keratopathy Cornea Endothelial dysfunction

Interventions

Performing CHCEC injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BSCVA under 0.5 corneal endothelial cell density unmesurable or under 500cells per mm2 Corneal thickness over 630 micro meter with corneal epithelial edema

Exclusion criteria

Exclusion criteria: corneal infection pregnant bleeding tendency mental disability uncontrolable glaucoma uncontrolable diabetes autoimmune disease cancer patient heart disease

Design outcomes

Primary

Measure	Time frame
Corneal Endothelial Cell Density > 500 cells/mm^2 (24W)	—

Secondary

Measure	Time frame
Corneal Endothelial Cell Density > 500 cells/mm^2 (52W, 104W) Corneal Thickness < 630 micro meter and no corneal epithelial edema (24W, 52W, 104W) Improvement of visual acuity (24W, 52W, 104W) Improvement of VFQ-25 (24W)	—

Countries

Japan

Contacts

Public ContactHiroshi Kubota

University Hospital, Kyoto Prefectural University of Medicine

byokanso@koto.kpu-m.ac.jp+81-75-251-5355

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026